REPORT ID 3821

EMEA (Europe, Middle East and Africa) Proliferative Diabetic Retinopathy Therapeutics Market Report 2017

Publish Date
14-Dec-17
Pages
102
Format
Electronic (PDF)

In this report, the EMEA Proliferative Diabetic Retinopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Proliferative Diabetic Retinopathy Therapeutics for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Proliferative Diabetic Retinopathy Therapeutics market competition by top manufacturers/players, with Proliferative Diabetic Retinopathy Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Acucela Inc
    Aerie Pharmaceuticals Inc
    Antisense Therapeutics Ltd
    Icon Bioscience Inc
    Ohr Pharmaceutical Inc
    PanOptica Inc
    Ribomic Inc
    ThromboGenics NV

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Ocriplasmin
    PAN-90806
    RBM-008
    Squalamine Lactate
    THR-687
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Proliferative Diabetic Retinopathy Therapeutics Market Report 2017
1 Proliferative Diabetic Retinopathy Therapeutics Overview
    1.1 Product Overview and Scope of Proliferative Diabetic Retinopathy Therapeutics
    1.2 Classification of Proliferative Diabetic Retinopathy Therapeutics
        1.2.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Ocriplasmin
        1.2.4 PAN-90806
        1.2.5 RBM-008
        1.2.6 Squalamine Lactate
        1.2.7 THR-687
        1.2.8 Others
    1.3 EMEA Proliferative Diabetic Retinopathy Therapeutics Market by Application/End Users
        1.3.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 EMEA Proliferative Diabetic Retinopathy Therapeutics Market by Region
        1.4.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Proliferative Diabetic Retinopathy Therapeutics (2012-2022)
        1.5.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Revenue and Growth Rate (2012-2022)

2 EMEA Proliferative Diabetic Retinopathy Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Market Competition by Players/Manufacturers
        2.1.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Proliferative Diabetic Retinopathy Therapeutics Sale Price by Players (2012-2017)
    2.2 EMEA Proliferative Diabetic Retinopathy Therapeutics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Proliferative Diabetic Retinopathy Therapeutics Sale Price by Type (2012-2017)
    2.3 EMEA Proliferative Diabetic Retinopathy Therapeutics (Volume) by Application
    2.4 EMEA Proliferative Diabetic Retinopathy Therapeutics (Volume and Value) by Region
        2.4.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales Price by Region (2012-2017)

3 Europe Proliferative Diabetic Retinopathy Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Proliferative Diabetic Retinopathy Therapeutics Sales and Value (2012-2017)
        3.1.1 Europe Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Proliferative Diabetic Retinopathy Therapeutics Revenue and Growth Rate (2012-2017)
    3.2 Europe Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Type
    3.3 Europe Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Application
    3.4 Europe Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Proliferative Diabetic Retinopathy Therapeutics Sales Volume by Countries (2012-2017)
        3.4.2 Europe Proliferative Diabetic Retinopathy Therapeutics Revenue by Countries (2012-2017)
        3.4.3 Germany Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        3.4.4 France Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        3.4.5 UK Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        3.4.6 Russia Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        3.4.7 Italy Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)

4 Middle East Proliferative Diabetic Retinopathy Therapeutics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales and Value (2012-2017)
        4.1.1 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Proliferative Diabetic Retinopathy Therapeutics Revenue and Growth Rate (2012-2017)
    4.2 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Type
    4.3 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Application
    4.4 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Proliferative Diabetic Retinopathy Therapeutics Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Proliferative Diabetic Retinopathy Therapeutics Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        4.4.4 Israel Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        4.4.5 UAE Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        4.4.6 Iran Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)

5 Africa Proliferative Diabetic Retinopathy Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Proliferative Diabetic Retinopathy Therapeutics Sales and Value (2012-2017)
        5.1.1 Africa Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Proliferative Diabetic Retinopathy Therapeutics Revenue and Growth Rate (2012-2017)
    5.2 Africa Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Type
    5.3 Africa Proliferative Diabetic Retinopathy Therapeutics Sales and Market Share by Application
    5.4 Africa Proliferative Diabetic Retinopathy Therapeutics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Proliferative Diabetic Retinopathy Therapeutics Sales Volume by Countries (2012-2017)
        5.4.2 Africa Proliferative Diabetic Retinopathy Therapeutics Revenue by Countries (2012-2017)
        5.4.3 South Africa Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate (2012-2017)

6 EMEA Proliferative Diabetic Retinopathy Therapeutics Manufacturers/Players Profiles and Sales Data
    6.1 Acucela Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Acucela Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Aerie Pharmaceuticals Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Aerie Pharmaceuticals Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Antisense Therapeutics Ltd
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Antisense Therapeutics Ltd Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Icon Bioscience Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Icon Bioscience Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Ohr Pharmaceutical Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Ohr Pharmaceutical Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 PanOptica Inc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 PanOptica Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Ribomic Inc
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Ribomic Inc Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 ThromboGenics NV
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Proliferative Diabetic Retinopathy Therapeutics Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 ThromboGenics NV Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 Proliferative Diabetic Retinopathy Therapeutics Manufacturing Cost Analysis
    7.1 Proliferative Diabetic Retinopathy Therapeutics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Proliferative Diabetic Retinopathy Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Proliferative Diabetic Retinopathy Therapeutics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Proliferative Diabetic Retinopathy Therapeutics Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Proliferative Diabetic Retinopathy Therapeutics Market Forecast (2017-2022)
    11.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Proliferative Diabetic Retinopathy Therapeutics Price and Trend Forecast (2017-2022)
    11.2 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Proliferative Diabetic Retinopathy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales Forecast by Type (2017-2022)
    11.7 EMEA Proliferative Diabetic Retinopathy Therapeutics Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer